ADMA Biologics (ADMA) Competitors

ADMA Biologics (NASDAQ:ADMA) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings.

Does the media prefer ADMA or GMAB?

In the previous week, Genmab A/S had 7 more articles in the media than ADMA Biologics. MarketBeat recorded 14 mentions for Genmab A/S and 7 mentions for ADMA Biologics. Genmab A/S's average media sentiment score of 1.04 beat ADMA Biologics' score of 0.80 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, ADMA or GMAB?

ADMA Biologics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.

Is ADMA or GMAB more profitable?

Genmab A/S has a net margin of 36.30% compared to ADMA Biologics' net margin of 17.80%. ADMA Biologics' return on equity of 53.20% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	17.80%	53.20%	26.07%
Genmab A/S	36.30%	16.78%	13.79%

Do analysts prefer ADMA or GMAB?

ADMA Biologics presently has a consensus target price of $21.25, indicating a potential upside of 34.15%. Genmab A/S has a consensus target price of $42.17, indicating a potential upside of 88.75%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Genmab A/S	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75

Do insiders & institutionals believe in ADMA or GMAB?

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 3.7% of ADMA Biologics shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has preferable earnings & valuation, ADMA or GMAB?

Genmab A/S has higher revenue and earnings than ADMA Biologics. Genmab A/S is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$258.21M	14.50	-$28.24M	$0.28	56.57
Genmab A/S	$3.12B	4.73	$1.14B	$1.74	12.84

Does the MarketBeat Community favor ADMA or GMAB?

ADMA Biologics received 249 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 72.08% of users gave ADMA Biologics an outperform vote while only 62.84% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
ADMA Biologics	Outperform Votes 413 72.08%	Underperform Votes 160 27.92%
Genmab A/S	Outperform Votes 164 62.84%	Underperform Votes 97 37.16%

Summary

ADMA Biologics and Genmab A/S tied by winning 9 of the 18 factors compared between the two stocks.